CARB-X

CARB-X. It is a global nonprofit partnership dedicated to accelerating the development of antibacterial products to address the rising threat of drug-resistant bacteria. Launched in 2016, its mission is to support the world's most innovative early-stage research and development projects targeting the most dangerous Gram-negative pathogens identified as critical priorities by the World Health Organization. With a funding model that combines support from governments and philanthropic organizations, it operates as one of the world's largest portfolios of preclinical antibacterial development.

Overview

Established as a response to the critical global health challenge of antimicrobial resistance, this partnership focuses exclusively on the early and high-risk stages of drug, vaccine, and diagnostic development. Its operational headquarters are in Boston, leveraging the city's dense biotechnology and academic research ecosystem. The initiative strategically fills the funding void often termed the "valley of death" in biopharmaceutical research, providing not only financial grants but also expert support in non-clinical development, regulatory affairs, and business development. This comprehensive approach aims to propel promising scientific innovations from the laboratory toward clinical trials and, ultimately, to patients.

History and funding

The partnership was formally launched in July 2016, following a commitment announced at the World Economic Forum. Initial core funding was provided by the U.S. Department of Health and Human Services through the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases, alongside the Wellcome Trust from the United Kingdom. In 2017, the German Federal Ministry of Education and Research joined as a major funder. A significant expansion occurred in 2022 with a new investment from the U.K. Government's Global Antimicrobial Resistance Innovation Fund. These substantial investments from public and philanthropic entities underscore the initiative's role as a critical component of the global AMR response, aligning with national action plans and the goals of the World Health Organization.

Strategic priorities and portfolio

The portfolio is rigorously focused on high-priority pathogens, particularly those on the WHO priority pathogens list, such as Acinetobacter baumannii, Pseudomonas aeruginosa, and members of the Enterobacteriaceae family. Strategic priorities include developing novel antibiotics, alternatives to antibiotics like bacteriophage therapies and lysins, rapid point-of-care diagnostics, and preventive vaccines. Projects are selected through a competitive, peer-reviewed process managed by expert reviewers from institutions like the Broad Institute and Imperial College London. The portfolio is dynamic, with projects progressing through stages and new awards made regularly to the most innovative science emerging from global applicants in academia, biotech startups, and small and medium-sized enterprises.

Key partnerships and governance

Governance and execution are managed through a network of premier global partners. Overall strategic direction is provided by Boston University, which acts as the global administrator. Key implementing partners include the Broad Institute for portfolio monitoring and the RTI International for non-clinical services. Critical support for business and product development strategy is provided by Massachusetts Biotechnology Council and the Wellcome Trust. This consortium model ensures that funded projects receive multifaceted support beyond capital, accessing world-class expertise in toxicology, chemistry manufacturing and controls, and intellectual property management. The partnership also collaborates closely with global bodies like the World Health Organization and the European Medicines Agency to align with international regulatory and public health priorities.

Impact and achievements

Since its inception, the partnership has become the world's largest public-private initiative of its kind, investing in hundreds of projects across more than a dozen countries. Its portfolio has advanced numerous candidates into Phase 1 and Phase 2 clinical trials, with several promising novel classes of antibiotics and rapid diagnostics progressing through development. Achievements include supporting the development of the first Gram-negative-targeting antibiotic from a new class in decades to enter clinical trials. The initiative's model has demonstrated success in de-risking early innovation, attracting follow-on investment from larger pharmaceutical companies and venture capital firms into the challenging antibacterial field, thereby helping to revitalize the entire antibiotic development pipeline.

Category:Antimicrobial resistance Category:Medical and health organizations based in Massachusetts Category:Public–private partnerships Category:Organizations established in 2016